A Phase 3 interventional study of SPD489 in Schizophrenia, sponsored by Shire. Terminated at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-22.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.
Among the 11 studies in Schizophrenia by Takeda, this one is the 9th largest by enrollment, is one of 4 that started in 2013, is one of 4 in phase 3, and was the 5th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 20 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Schizophrenia by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
Not required
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPD489
Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
Also known as: lisdexamfetamine dimesylate, LDX, Vyvanse
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks
Time frame: Basline and 52 weeks
Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks
Time frame: Baseline and 52 weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to 52 weeks
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks
Time frame: Baseline and 52 weeks
Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale
Time frame: Baseline and week 52
Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale
Time frame: Up to 52 weeks
Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks
Time frame: Baseline and 52 weeks
| Milestone | SPD489 |
|---|---|
| Started | 0 |
| Completed | 0 |
| Not completed | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD489 | — | — | — |
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized
| Age, Categorical | SPD489 |
|---|---|
| <=18 years | — |
| Between 18 and 65 years | — |
| >=65 years | — |
| Sex: Female, Male | SPD489 |
|---|---|
| Female | — |
| Male | — |
| Region of Enrollment | SPD489 |
|---|
Ran from Feb 2013 to primary completion in Apr 2013, 2 months.
Results were first posted in May 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine